Palmiero et al.26 showed that TAPSE/sPAP was an independent predictor of cardiovascular death and had potential to improve risk stratification and guide management strategies in patients with amyloid cardiomyopathy. This evidence concerns the gene PDZK1IP1 and cardiac amyloidosis.